by Madaline Spencer | Feb 3, 2025
Christopher Patriquin, MD, University of Toronto, discusses results of a clinical trial comparing combination C5 inhibitor therapy versus standard of care in patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare clonal hematopoietic stem...
by Madaline Spencer | Jan 30, 2025
Elias Mai, MD, Heidelberg Myeloma Center, discusses the GMMG-HD7 clinical trial for patients with multiple myeloma. Multiple myeloma is a bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic...
by Madaline Spencer | Jan 28, 2025
Pieter Sonneveld, MD, Erasmus MC Cancer Institute, discusses results from the PERSEUS clinical trial for patients with multiple myeloma. Multiple myeloma is a bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal...
by Madaline Spencer | Jan 27, 2025
Elias Jabbour, MD, MD Anderson Cancer Center, University of Texas, discusses results of a clinical trial evaluating bleximenib for patients with acute leukemia. Acute myeloid leukemias are a group of neoplasms arising from precursor cells committed to...
by Madaline Spencer | Jan 24, 2025
Martin Dreyling, MD, Ludwig Maximilian University of Munich, discusses results of the TRIANGLE study testing the addition of ibrutinib to treat mantle cell lymphoma. Mantle cell lymphoma is a rare form of malignant non-Hodgkin lymphoma affecting B...
